N4 Pharma (N4P) Competitors GBX 0.70 +0.05 (+7.69%) (As of 03:23 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitors N4P vs. CHLL, MXC, RGT, HELD, HLN, HIK, HCM, INDV, AMYT, and APHShould you be buying N4 Pharma stock or one of its competitors? The main competitors of N4 Pharma include Chill Brands Group (CHLL), Argent BioPharma (MXC), Argent BioPharma (RGT), Hellenic Dynamics (HELD), Haleon (HLN), Hikma Pharmaceuticals (HIK), HUTCHMED (HCM), Indivior (INDV), Amryt Pharma (AMYT), and Alliance Pharma (APH). These companies are all part of the "drug manufacturers - specialty & generic" industry. N4 Pharma vs. Chill Brands Group Argent BioPharma Argent BioPharma Hellenic Dynamics Haleon Hikma Pharmaceuticals HUTCHMED Indivior Amryt Pharma Alliance Pharma Chill Brands Group (LON:CHLL) and N4 Pharma (LON:N4P) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk. Does the media refer more to CHLL or N4P? In the previous week, Chill Brands Group's average media sentiment score of 0.47 beat N4 Pharma's score of 0.00 indicating that Chill Brands Group is being referred to more favorably in the media. Company Overall Sentiment Chill Brands Group Neutral N4 Pharma Neutral Is CHLL or N4P more profitable? N4 Pharma's return on equity of -82.39% beat Chill Brands Group's return on equity.Company Net Margins Return on Equity Return on Assets Chill Brands GroupN/A -2,802.21% -44.64% N4 Pharma N/A -82.39%-56.00% Do insiders and institutionals have more ownership in CHLL or N4P? 0.2% of Chill Brands Group shares are owned by institutional investors. 24.2% of Chill Brands Group shares are owned by company insiders. Comparatively, 18.0% of N4 Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has better earnings & valuation, CHLL or N4P? N4 Pharma has lower revenue, but higher earnings than Chill Brands Group. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChill Brands Group£624.19K17.44-£3.64M-£0.01-215.00N4 Pharma£23.52K117.47-£1.08MN/AN/A Does the MarketBeat Community favor CHLL or N4P? N4 Pharma received 97 more outperform votes than Chill Brands Group when rated by MarketBeat users. However, 66.67% of users gave Chill Brands Group an outperform vote while only 65.61% of users gave N4 Pharma an outperform vote. CompanyUnderperformOutperformChill Brands GroupOutperform Votes666.67% Underperform Votes333.33% N4 PharmaOutperform Votes10365.61% Underperform Votes5434.39% Which has more volatility & risk, CHLL or N4P? Chill Brands Group has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500. Comparatively, N4 Pharma has a beta of -0.37, indicating that its share price is 137% less volatile than the S&P 500. SummaryChill Brands Group beats N4 Pharma on 7 of the 12 factors compared between the two stocks. Ad Brownstone ResearchBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.I believe we are about to do it again with this new AI project called Stargate Get N4 Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for N4P and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart N4P vs. The Competition Export to ExcelMetricN4 PharmaDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£2.76M£1.30B£5.15B£1.39BDividend Yield3.12%3.13%7.58%11.73%P/E Ratio-55.00101.66133.641,558.46Price / Sales117.471,990.241,353.28212,359.52Price / Cash2.2510.3737.5632.93Price / BookN/A2.876.432.81Net Income-£1.08M£156.06M£117.54M£152.70M7 Day Performance-2.64%-0.43%-3.14%4.23%1 Month Performance16.67%-3.66%-4.56%2.82%1 Year Performance-9.68%93.50%29.07%119.67% N4 Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)N4PN4 PharmaN/AGBX 0.70+7.7%N/A-16.1%£2.76M£23,524.00-55.005Gap DownCHLLChill Brands GroupN/AGBX 2.15flatN/AN/A£10.89M£624,187.00-215.007MXCArgent BioPharmaN/AGBX 22+4.8%N/AN/A£9.65M£1.32M-13.255Gap UpRGTArgent BioPharmaN/AGBX 17.25+4.5%N/AN/A£9.25MN/A-71.88N/AGap UpHELDHellenic DynamicsN/AGBX 0.95flatN/AN/A£1.40MN/A0.00N/ANews CoverageHLNHaleon1.2663 of 5 starsGBX 367.80+0.6%GBX 415+12.8%+11.9%£33.25B£11.26B3,065.0025,408Positive NewsHIKHikma Pharmaceuticals2.2317 of 5 starsGBX 1,839+1.1%GBX 2,383.33+29.6%+3.3%£4.08B£3.02B2,829.239,100HCMHUTCHMEDN/AGBX 265.49+0.2%N/A-10.6%£2.27B£610.81M-6,637.351,760Positive NewsINDVIndivior2.1673 of 5 starsGBX 784.50+2.0%GBX 1,500+91.2%-42.2%£1.01B£1.15B-980.631,000AMYTAmryt PharmaN/AGBX 143-11.7%N/A+0.0%£457.11M£210.24M-4.33290Gap DownAPHAlliance Pharma2.6188 of 5 starsGBX 46.23+0.5%GBX 60+29.8%+30.2%£249.93M£183.15M-770.5791,000Gap Up Related Companies and Tools Related Companies Chill Brands Group Alternatives Argent BioPharma Alternatives Argent BioPharma Alternatives Hellenic Dynamics Alternatives Haleon Alternatives Hikma Pharmaceuticals Alternatives HUTCHMED Alternatives Indivior Alternatives Amryt Pharma Alternatives Alliance Pharma Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:N4P) was last updated on 11/19/2024 by MarketBeat.com Staff From Our PartnersTop "Sleeping Giant" Crypto In The Market NowTop "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your fi...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding N4 Pharma Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share N4 Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
